Generally, Fosamax common side effects manifest as stomachache, hardened or liquid stool, nausea, acid stomach, and acid regurgitation. Less commonly, users experience swelling of the joints, giddiness, gaseous distention, vomiting, taste-blindness, headache, and ulcers in the esophagus. Normally, such side effects are not troublesome and recede or fade out within the first several days of starting the therapy.
Another kind of pain associated with this drug is strictly musculoskeletal. The FDA put up a public warning about this painful effect in 2008, as it the commission believed the drug’s leaflet did not put a sufficient emphasis on this particular debilitating hazard.
Rare side effects: Necrosis of bones
Osteonecrosis means atrophic processes in the bone tissue. Alendronate side effects comprise an increased risk for maxillary necrosis (which refers specifically to the destruction of the jaw bone), especially in connection with dental works (e.g., tooth removal). As an infection sets in the affected area, the disrupted gum tissue exposes the maxillary bone. The result of this is the bone breaking off and decaying.
The maxillary necrotic syndrome can be especially problematic because of the latent initial phases. Similarly to femur breakages, this issue is caused by the active agent as it stops natural reparative processes and osteoclast action in the bones.
Fosamax drug interactions and other issues
This drug does not agree well with aminoglycoside antibiotics due to the high hazard of decreased body calcium levels. The opposite is also true: calcium-based medications and additives lower the absorption of alendronate and should be administered with a minimal spacing of 2 hours. Also, patients are likely to experience upper gastro-intestinal adverse events when combining Fosamax with aspirin or nonsteroidal anti-inflammatory drugs.
Altered bioavailability is possible when the active amount of the object medicine in the bloodstream is perpetrated by another medicine. For drugs taken by mouth, this occurs in connection with the alteration of metabolic absorption. Primarily, this is typical for medicines with low rather than high oral bioavailability. Having comparatively weak bioavailability, alendronate should not be co-administered with calcium that tends to outbalance its absorption.
Fosamax withdrawal symptoms
Withdrawal syndrome is observed among users of this drug, especially female patients of 50-59 years of age who have stayed on Fosamax for 5-10 years, also co-used medication Lyrica, and have had a depressed state. The details of this study made available by eHealthMe come from the analysis of 83,217 cases. Withdrawal issues have been testified by people with stress, depressive states, anxiety, chronic pain, and fibromyalgia.
Female users who stopped taking alendronate after a period of 5 years demonstrated a moderate drop in BMD and a steady increase in biochemical markers. Nevertheless, there were but no increased fracture risks other than for condition-related vertebral breakages as compared with patients who continued the medicine. This invites the suggestion that, for the majority of women, termination of the therapy in a less than 5 year period does not influence the fracture hazard significantly. At the same time, women facing an especially high risk of condition-related vertebral breakages may benefit from staying on the drug beyond 5 years.